Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ICVX - Icosavax, Inc.

IEX Last Trade
15.34
7.230   47.132%

Share volume: 0
Last Updated: Fri 16 Feb 2024 10:00:00 PM CET
Biological Product (except Diagnostic) Manufacturing : -4.32%

PREVIOUS CLOSE
CHG
CHG%
$8.11
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
76%
Profitability 93%
Dept financing 25%
Liquidity 0%
Performance 90%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-2.23%
2 Year
76.79%
Key data
Stock price
$15.34
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$15.26 - $15.88
52 WEEK CHANGE
-$2.36
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
50.090 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Adam K. Simpson
Region: US
Website: icosavax.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.

Recent news